Aurobindo, Glenmark and Zydus recall products in the US market
All three Indian pharma companies have initiated the recall due to quality concerns.
15 December, 2024•2 min
0
15 December, 2024•2 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
SUBSCRIBE
Already have an account? Sign In
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
Business
Star manager’s impending retirement threatens to stymie ICICI Pru MF’s race to the top
Sankaren Naren’s risk-adjusted returns strategy has worked wonders for the fund house, putting it within reach of the top spot. The good run now hinges on a clear succession plan.
You may also like
Business
Dr. Reddy’s wants to be India’s fifth largest drugmaker. What will it take?
The stock market has taken note of the company’s ambitious plans in the domestic market. But the path ahead is far from easy.
Internet
Why quick delivery of medicines will be difficult to scale
Quick-commerce apps are likely to run into regulations and poor order volumes as they try to grow this business.
Health
Indian pharma exporters protesting against new regulations is not a good look
The rules require exporters of certain drugs to get an NOC from importing countries—a small but much-needed step to restoring India’s credibility in the global pharma market.
